Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920257 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase 1 study of Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 7
- Study locations
NCT00920257: Completed Phase 1 study of Cancer, sponsored by GlaxoSmithKline.
NCT00920257 is a Phase 1 study of Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 77 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920257, a Phase 1 study of Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.
Conditions Studied
Interventions
- DRUG GSK2141795
Study Locations (7)
Maryland
- GSK Investigational Site - Baltimore
Massachusetts
- GSK Investigational Site - Boston
New York
- GSK Investigational Site - New York
Oklahoma
- GSK Investigational Site - Oklahoma City
Tennessee
- GSK Investigational Site - Nashville
Texas
- GSK Investigational Site - Houston
Ontario
- GSK Investigational Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-06-16 |
| Est. Completion | 2013-04-17 |
| Phase | Phase 1 |
What the finished NCT00920257 record still lists
NCT00920257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which GSK2141795 is the first listed.
NCT00920257 lists 7 locations in 7 states (Maryland, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT00920257 about?
NCT00920257 is a clinical study titled "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795". This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.
What is the current status of trial NCT00920257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2009-06-16. Estimated completion is 2013-04-17.
What conditions does trial NCT00920257 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00920257?
The interventions under investigation include: GSK2141795 (DRUG).
Who is sponsoring clinical trial NCT00920257?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920257 being conducted?
This trial has 7 study locations across Maryland, Massachusetts, New York, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920257's enrollment target sits among peer trials
77 364th of 615 higher than 251 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI